EDWARD G. PARENT

PROFILE

R&D scientist with over 25 years experience in the Medical Device industry. I work in field of biomaterials developing and testing the biocompatibility, safety and efficacy of products. I have developed polymeric drug delivery systems and biomaterials for use in osteoarthritis, soft tissue augmentation, rheumatoid arthritis, ophthalmic as well as products for use in topical skin care. I have experience in bringing products from bench top to large scale production, and have a general knowledge of FDA requirements in the medical device.

PROFESSIONAL EXPERIENCE

2003 - 2010 Hylamed Inc / LuroMed LLC Tarrytown, NY

Director of Operations / Scientist

 Develop new biomaterials based on natural polymers and silicone.

 Develop drug delivery products for topical skin care..

 Patented polymeric biomaterial for topical skin care and Dermal filler.

 Developed process to manufacture 1500kg batches of product in one day, previously 40kg batches in 5 days, making the process practical.

 Supervised the production of Biocare product line marketed by Dow Chemical and Hylasome marketed by Lipo Chemical. Responsible for QA, keeping Batch Records, Certificates of Analysis, and authorize batch release.

 Set up a new research lab, analytical lab, and a production facility.

 Set up system of QC and QA in compliance with FDA Regulations.

2000-2002 GENZYME BIOSURGERY Ridgefield, NJ

Staff Scientist I

Worked in large groups on several projects simultaneously to develop new drug delivery systems, new polymeric based biomaterials, and to develop and scale up new products. Some projects I worked on include:

 Drug delivery to the ear for vertigo

 Cardiac delivery for atrial fibrillation

 Intraarticular delivery for cartilage repair.

 Development of coating for a drug eluting stent

 Develop and scale up new arthritis device

 Targeted drug delivery

 Corneal wound healing

 Atomic Force Microscopy

Radiation Safety Officer

1983-2000 BIOMATRIX INC Ridgefield, NJ

Scientist

Worked at a start-up company with 9 other people, Biomatrix grew to a company with 500+ employees worth $750M. Worked to develop biomaterials marketed as medical products such as Synvisc, Hylaform, and Hylashield.

Developed and implemented biocompatibility testing procedures for biomaterials

including:

in-vitro compatibility with blood and tissue

Immune response and ELISA development

Degradation and metabolic clearance studies.

Studied hyaluronan in bodily fluids, i.e. the vitreous and synovial fluid

Studied receptor binding, endocytosis, cell adhesion, and proliferation

Purified and characterized enzymes, and proteins

Tissue culture and organ culture.

Write SOP’s, Protocol’s, Reports.

Developed and evaluated a platform of Drug Delivery Systems for a variety of applications including: Antibiotics, Antineoplastics, antisense drugs, Peptides, Growth Factors, Antiangiogenics, small drugs, Interferon, etc by various routes such as:

subcutaneous, intravascular, intraarticular, ophthalmic, topical, implant

EDUCATION

 1984-1985 Graduate Center of the City University of New York

New York, New York

Graduate courses in Biochemistry and Cell Biology

 1978-1982 SUNY@ Old Westbury Old Westbury, New York

BS. in Biology

AWARDS AND HONORS

Biomatrix Accomplishment Award 1984

Biomatrix Achievement Award 1988

Who’s Who in Science and Engineering 1994 – 1995

PUBLICATIONS IN JOURNALS

Larsen, N. E., Leshchiner, E. A., Parent, E., Hendreikson, J., Balazs,

Hial, S. K. (1991) Hylan gel Composition for Percutaneous Embolization.

J. Biomed. Mater. Res. 25:699-710

Larsen, N. E., Lombard, K., Parent, E., Balazs, E. A. (1992) Effects of

Hylan on Cartilage and Chondrocyte Cultures. J. Orthop Res. 10:23-32

ABSTRACTS

Parent, E., Mess, D., Larsen, N. E., Dennebaum, R., Pollak, C.

Biologically Active Hyaluronan Conjugates of Alpha-Interferon and Their

Synthesis. Control Release Society 2002

Gianolio, D. A., Fustino, N., Calias, P., Johnson, E., Parent, E.,

Shiedlin, A., Yu, L., Miller, R. Cross-Linked Sodium Hyaluronate

Containing Labile Linkages. Society for Biomaterials 2002

Balazs, E. A., Larsen, N. E., Leshchiner, Parent, E., Boney, J.,

Mitlitski, V., Whetstone, J.

Dry Film to Prevent Adhesion Between Two Healing Tissue Surfaces.

Hyaluronan 2000, September 4, 2000

Larsen, N. E., Leshchiner, E. A., Parent, E., Balazs, E. A. Release of

Gentamicin from Hylan Vehicles. Society for Biomaterials, May 1-5, 1991

Larsen, N. E., Leshchiner, E. A., Parent, E., Hendreikson, J., Balazs,

E. A. Local intravascular Drug Delivery via Percutaneous Embolization

with Hylan Gel. Society for Biomaterials, April 28, 1989. Lake Buena

Vista, Fl

CHAPTERS IN BOOKS

1991 Larsen, N. E., Leshchiner, E. A., Parent, E., Balazs, E. A. Hylan

and Hylan derivatives in Drug Delivery. In Cosmetic and Pharmaceutical

Applications of Polymers, pp147-157, New York, Plenum Press

PODIUM PRESENTATIONS

Parent, E., Mess, D., Larsen, N. E., Dennebaum, R., Pollak, C.

Biologically Active Hyaluronan Conjugates of Alpha-Interferon and Their Synthesis. Control Release Society July 2002, Seoul, Korea

PUBLISHED PATENTS

Cross-linked gels of hyaluronic acid with hydrophobic polymers and processes for making them.

Leshchiner A., Larsen N. E., Parent E. G.

Patent number: US 7,521,434 Publication date: April 21, 2009

Hydrophilic Biopolymer-Drug Conjugates, Their Preparation and use.

Parent E G., Larsen, N. E.

Patent number: US7034127 Publication date: April 25, 2006

Hyaluronan-Based Anti-adhesion Compositions, Their Preparation and Use.

Patent number: WO0217853 A, Publication date: March 07, 2002

Balazs, E. A., Leshchiner A., Larsen, N. E., Mitlitski, V., Hendreikson, J.,

Parent, E. G.,

Modified Hydrophilic Polymers Containing Hydrophobic Groups.

Registration No 24,429, Filed: September 24, 2009

Parent, E. G., Leshchiner A., Larsen, N. E.

Contact this candidate